

# Global Therapeutic Monoclonal Antibodies Drug Market Growth 2026-2032

<https://marketpublishers.com/r/GFF0370EDA4DEN.html>

Date: April 2026

Pages: 139

Price: US\$ 3,660.00 (Single User License)

ID: GFF0370EDA4DEN

## Abstracts

The global Therapeutic Monoclonal Antibodies Drug market size is predicted to grow from US\$ 211040 million in 2025 to US\$ 443540 million in 2032; it is expected to grow at a CAGR of 11.4% from 2026 to 2032.

Monoclonal antibodies (MABs) are a type of targeted drug therapy. These drugs recognise and find specific proteins on cancer cells. There are many different MABs to treat cancer. They work in different ways to kill the cancer cell or stop it from growing.

The Therapeutic Antibodies Drug Market is driven by the remarkable potential of therapeutic antibodies to treat a diverse array of diseases, from cancer and autoimmune disorders to infectious diseases. Monoclonal antibodies have gained prominence as highly targeted and effective therapeutic agents that can modulate the immune system, neutralize pathogens, and inhibit disease-associated proteins. As precision medicine and biopharmaceutical innovations continue to advance, the demand for therapeutic antibodies grows. Innovations in antibody design, engineering, and manufacturing technologies further contribute to market expansion. Nevertheless, a significant challenge for this market is the need to address high production costs, optimize therapeutic antibody development processes, and navigate complex regulatory pathways while ensuring accessibility and affordability for patients. Overcoming manufacturing complexities, managing research and development costs, and addressing regulatory standards are ongoing challenges. Additionally, the market faces competition from small molecules and other biologic therapies, necessitating continuous research and development efforts to unlock the full therapeutic potential of therapeutic antibodies. Striking a balance between providing safe, effective, and accessible therapeutic antibody drugs while addressing scientific and regulatory challenges is essential for the continued growth of the Therapeutic Antibodies Drug Market.

LP Information, Inc. (LPI) ' newest research report, the “Therapeutic Monoclonal Antibodies Drug Industry Forecast” looks at past sales and reviews total world Therapeutic Monoclonal Antibodies Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected Therapeutic Monoclonal Antibodies Drug sales for 2026 through 2032. With Therapeutic Monoclonal Antibodies Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Therapeutic Monoclonal Antibodies Drug industry.

This Insight Report provides a comprehensive analysis of the global Therapeutic Monoclonal Antibodies Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Therapeutic Monoclonal Antibodies Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Therapeutic Monoclonal Antibodies Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Therapeutic Monoclonal Antibodies Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Therapeutic Monoclonal Antibodies Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Therapeutic Monoclonal Antibodies Drug market by product type, application, key manufacturers and key regions and countries.

### **Segmentation by Type:**

Mouse-derived Antibodies

Chimeric Antibodies

Humanized Antibodies

**Segmentation by Application:**

Immune Diseases

Cancer

Other

**This report also splits the market by region:**

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

AbbVie

Johnson & Johnson

Novartis

Gilead Sciences

Roche

Bristol-Myers Squibb

Amgen

AstraZeneca

Merck & Co

Takeda

Merck KGaA

Seagen

Eli Lilly

Ono Pharmaceutical

Pfizer

Regeneron

Innovent

Hengrui Medicine

## **Key Questions Addressed in this Report**

What is the 10-year outlook for the global Therapeutic Monoclonal Antibodies Drug market?

What factors are driving Therapeutic Monoclonal Antibodies Drug market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Therapeutic Monoclonal Antibodies Drug market opportunities vary by end market size?

How does Therapeutic Monoclonal Antibodies Drug break out by Type, by Application?

## Contents

### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

### 2 EXECUTIVE SUMMARY

#### 2.1 World Market Overview

- 2.1.1 Global Therapeutic Monoclonal Antibodies Drug Annual Sales 2021-2032
- 2.1.2 World Current & Future Analysis for Therapeutic Monoclonal Antibodies Drug by Geographic Region, 2021, 2025 & 2032
- 2.1.3 World Current & Future Analysis for Therapeutic Monoclonal Antibodies Drug by Country/Region, 2021, 2025 & 2032

#### 2.2 Therapeutic Monoclonal Antibodies Drug Segment by Type

- 2.2.1 Mouse-derived Antibodies
- 2.2.2 Chimeric Antibodies
- 2.2.3 Humanized Antibodies
- 2.2.4 Therapeutic Monoclonal Antibodies Drug Sales by Type
  - 2.2.4.1 Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Type (2021-2026)
  - 2.2.4.2 Global Therapeutic Monoclonal Antibodies Drug Revenue and Market Share by Type (2021-2026)
  - 2.2.4.3 Global Therapeutic Monoclonal Antibodies Drug Sale Price by Type (2021-2026)

#### 2.3 Therapeutic Monoclonal Antibodies Drug Segment by Application

- 2.3.1 Immune Diseases
- 2.3.2 Cancer
- 2.3.3 Other
- 2.3.4 Therapeutic Monoclonal Antibodies Drug Sales by Application
  - 2.3.4.1 Global Therapeutic Monoclonal Antibodies Drug Sale Market Share by Application (2021-2026)

2.3.4.2 Global Therapeutic Monoclonal Antibodies Drug Revenue and Market Share by Application (2021-2026)

2.3.4.3 Global Therapeutic Monoclonal Antibodies Drug Sale Price by Application (2021-2026)

### **3 GLOBAL BY COMPANY**

3.1 Global Therapeutic Monoclonal Antibodies Drug Breakdown Data by Company

3.1.1 Global Therapeutic Monoclonal Antibodies Drug Annual Sales by Company (2021-2026)

3.1.2 Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Company (2021-2026)

3.2 Global Therapeutic Monoclonal Antibodies Drug Annual Revenue by Company (2021-2026)

3.2.1 Global Therapeutic Monoclonal Antibodies Drug Revenue by Company (2021-2026)

3.2.2 Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Company (2021-2026)

3.3 Global Therapeutic Monoclonal Antibodies Drug Sale Price by Company

3.4 Key Manufacturers Therapeutic Monoclonal Antibodies Drug Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Therapeutic Monoclonal Antibodies Drug Product Location Distribution

3.4.2 Players Therapeutic Monoclonal Antibodies Drug Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

### **4 WORLD HISTORIC REVIEW FOR THERAPEUTIC MONOCLONAL ANTIBODIES DRUG BY GEOGRAPHIC REGION**

4.1 World Historic Therapeutic Monoclonal Antibodies Drug Market Size by Geographic Region (2021-2026)

4.1.1 Global Therapeutic Monoclonal Antibodies Drug Annual Sales by Geographic Region (2021-2026)

4.1.2 Global Therapeutic Monoclonal Antibodies Drug Annual Revenue by Geographic Region (2021-2026)

- 4.2 World Historic Therapeutic Monoclonal Antibodies Drug Market Size by Country/Region (2021-2026)
  - 4.2.1 Global Therapeutic Monoclonal Antibodies Drug Annual Sales by Country/Region (2021-2026)
  - 4.2.2 Global Therapeutic Monoclonal Antibodies Drug Annual Revenue by Country/Region (2021-2026)
- 4.3 Americas Therapeutic Monoclonal Antibodies Drug Sales Growth
- 4.4 APAC Therapeutic Monoclonal Antibodies Drug Sales Growth
- 4.5 Europe Therapeutic Monoclonal Antibodies Drug Sales Growth
- 4.6 Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales Growth

## **5 AMERICAS**

- 5.1 Americas Therapeutic Monoclonal Antibodies Drug Sales by Country
  - 5.1.1 Americas Therapeutic Monoclonal Antibodies Drug Sales by Country (2021-2026)
  - 5.1.2 Americas Therapeutic Monoclonal Antibodies Drug Revenue by Country (2021-2026)
- 5.2 Americas Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026)
- 5.3 Americas Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

## **6 APAC**

- 6.1 APAC Therapeutic Monoclonal Antibodies Drug Sales by Region
  - 6.1.1 APAC Therapeutic Monoclonal Antibodies Drug Sales by Region (2021-2026)
  - 6.1.2 APAC Therapeutic Monoclonal Antibodies Drug Revenue by Region (2021-2026)
- 6.2 APAC Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026)
- 6.3 APAC Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia

## 6.10 China Taiwan

## **7 EUROPE**

### 7.1 Europe Therapeutic Monoclonal Antibodies Drug by Country

#### 7.1.1 Europe Therapeutic Monoclonal Antibodies Drug Sales by Country (2021-2026)

#### 7.1.2 Europe Therapeutic Monoclonal Antibodies Drug Revenue by Country (2021-2026)

### 7.2 Europe Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026)

### 7.3 Europe Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026)

### 7.4 Germany

### 7.5 France

### 7.6 UK

### 7.7 Italy

### 7.8 Russia

## **8 MIDDLE EAST & AFRICA**

### 8.1 Middle East & Africa Therapeutic Monoclonal Antibodies Drug by Country

#### 8.1.1 Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales by Country (2021-2026)

#### 8.1.2 Middle East & Africa Therapeutic Monoclonal Antibodies Drug Revenue by Country (2021-2026)

### 8.2 Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026)

### 8.3 Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026)

### 8.4 Egypt

### 8.5 South Africa

### 8.6 Israel

### 8.7 Turkey

### 8.8 GCC Countries

## **9 MARKET DRIVERS, CHALLENGES AND TRENDS**

### 9.1 Market Drivers & Growth Opportunities

### 9.2 Market Challenges & Risks

### 9.3 Industry Trends

## **10 MANUFACTURING COST STRUCTURE ANALYSIS**

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Therapeutic Monoclonal Antibodies Drug

10.3 Manufacturing Process Analysis of Therapeutic Monoclonal Antibodies Drug

10.4 Industry Chain Structure of Therapeutic Monoclonal Antibodies Drug

## **11 MARKETING, DISTRIBUTORS AND CUSTOMER**

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Therapeutic Monoclonal Antibodies Drug Distributors

11.3 Therapeutic Monoclonal Antibodies Drug Customer

## **12 WORLD FORECAST REVIEW FOR THERAPEUTIC MONOCLONAL ANTIBODIES DRUG BY GEOGRAPHIC REGION**

12.1 Global Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Region

12.1.1 Global Therapeutic Monoclonal Antibodies Drug Forecast by Region (2027-2032)

12.1.2 Global Therapeutic Monoclonal Antibodies Drug Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Therapeutic Monoclonal Antibodies Drug Forecast by Type (2027-2032)

12.7 Global Therapeutic Monoclonal Antibodies Drug Forecast by Application (2027-2032)

## **13 KEY PLAYERS ANALYSIS**

13.1 AbbVie

13.1.1 AbbVie Company Information

13.1.2 AbbVie Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

13.1.3 AbbVie Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)

- 13.1.4 AbbVie Main Business Overview
- 13.1.5 AbbVie Latest Developments
- 13.2 Johnson & Johnson
  - 13.2.1 Johnson & Johnson Company Information
  - 13.2.2 Johnson & Johnson Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications
  - 13.2.3 Johnson & Johnson Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.2.4 Johnson & Johnson Main Business Overview
  - 13.2.5 Johnson & Johnson Latest Developments
- 13.3 Novartis
  - 13.3.1 Novartis Company Information
  - 13.3.2 Novartis Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications
  - 13.3.3 Novartis Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.3.4 Novartis Main Business Overview
  - 13.3.5 Novartis Latest Developments
- 13.4 Gilead Sciences
  - 13.4.1 Gilead Sciences Company Information
  - 13.4.2 Gilead Sciences Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications
  - 13.4.3 Gilead Sciences Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.4.4 Gilead Sciences Main Business Overview
  - 13.4.5 Gilead Sciences Latest Developments
- 13.5 Roche
  - 13.5.1 Roche Company Information
  - 13.5.2 Roche Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications
  - 13.5.3 Roche Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.5.4 Roche Main Business Overview
  - 13.5.5 Roche Latest Developments
- 13.6 Bristol-Myers Squibb
  - 13.6.1 Bristol-Myers Squibb Company Information
  - 13.6.2 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications
  - 13.6.3 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Sales, Revenue,

## Price and Gross Margin (2021-2026)

13.6.4 Bristol-Myers Squibb Main Business Overview

13.6.5 Bristol-Myers Squibb Latest Developments

## 13.7 Amgen

13.7.1 Amgen Company Information

13.7.2 Amgen Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

13.7.3 Amgen Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.7.4 Amgen Main Business Overview

13.7.5 Amgen Latest Developments

## 13.8 AstraZeneca

13.8.1 AstraZeneca Company Information

13.8.2 AstraZeneca Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

13.8.3 AstraZeneca Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.8.4 AstraZeneca Main Business Overview

13.8.5 AstraZeneca Latest Developments

## 13.9 Merck & Co

13.9.1 Merck & Co Company Information

13.9.2 Merck & Co Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

13.9.3 Merck & Co Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.9.4 Merck & Co Main Business Overview

13.9.5 Merck & Co Latest Developments

## 13.10 Takeda

13.10.1 Takeda Company Information

13.10.2 Takeda Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

13.10.3 Takeda Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.10.4 Takeda Main Business Overview

13.10.5 Takeda Latest Developments

## 13.11 Merck KGaA

13.11.1 Merck KGaA Company Information

13.11.2 Merck KGaA Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

13.11.3 Merck KGaA Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.11.4 Merck KGaA Main Business Overview

13.11.5 Merck KGaA Latest Developments

13.12 Seagen

13.12.1 Seagen Company Information

13.12.2 Seagen Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

13.12.3 Seagen Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.12.4 Seagen Main Business Overview

13.12.5 Seagen Latest Developments

13.13 Eli Lilly

13.13.1 Eli Lilly Company Information

13.13.2 Eli Lilly Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

13.13.3 Eli Lilly Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.13.4 Eli Lilly Main Business Overview

13.13.5 Eli Lilly Latest Developments

13.14 Ono Pharmaceutical

13.14.1 Ono Pharmaceutical Company Information

13.14.2 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

13.14.3 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.14.4 Ono Pharmaceutical Main Business Overview

13.14.5 Ono Pharmaceutical Latest Developments

13.15 Pfizer

13.15.1 Pfizer Company Information

13.15.2 Pfizer Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

13.15.3 Pfizer Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.15.4 Pfizer Main Business Overview

13.15.5 Pfizer Latest Developments

13.16 Regeneron

13.16.1 Regeneron Company Information

13.16.2 Regeneron Therapeutic Monoclonal Antibodies Drug Product Portfolios and

## Specifications

13.16.3 Regeneron Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.16.4 Regeneron Main Business Overview

13.16.5 Regeneron Latest Developments

## 13.17 Innovent

13.17.1 Innovent Company Information

13.17.2 Innovent Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

13.17.3 Innovent Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.17.4 Innovent Main Business Overview

13.17.5 Innovent Latest Developments

## 13.18 Hengrui Medicine

13.18.1 Hengrui Medicine Company Information

13.18.2 Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

13.18.3 Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.18.4 Hengrui Medicine Main Business Overview

13.18.5 Hengrui Medicine Latest Developments

## **14 RESEARCH FINDINGS AND CONCLUSION**

## List Of Tables

### LIST OF TABLES

- Table 1. Therapeutic Monoclonal Antibodies Drug Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Table 2. Therapeutic Monoclonal Antibodies Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)
- Table 3. Major Players of Mouse-derived Antibodies
- Table 4. Major Players of Chimeric Antibodies
- Table 5. Major Players of Humanized Antibodies
- Table 6. Global Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026) & (Tons)
- Table 7. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Type (2021-2026)
- Table 8. Global Therapeutic Monoclonal Antibodies Drug Revenue by Type (2021-2026) & (\$ million)
- Table 9. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Type (2021-2026)
- Table 10. Global Therapeutic Monoclonal Antibodies Drug Sale Price by Type (2021-2026) & (US\$/Ton)
- Table 11. Global Therapeutic Monoclonal Antibodies Drug Sale by Application (2021-2026) & (Tons)
- Table 12. Global Therapeutic Monoclonal Antibodies Drug Sale Market Share by Application (2021-2026)
- Table 13. Global Therapeutic Monoclonal Antibodies Drug Revenue by Application (2021-2026) & (\$ million)
- Table 14. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Application (2021-2026)
- Table 15. Global Therapeutic Monoclonal Antibodies Drug Sale Price by Application (2021-2026) & (US\$/Ton)
- Table 16. Global Therapeutic Monoclonal Antibodies Drug Sales by Company (2021-2026) & (Tons)
- Table 17. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Company (2021-2026)
- Table 18. Global Therapeutic Monoclonal Antibodies Drug Revenue by Company (2021-2026) & (\$ millions)
- Table 19. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Company (2021-2026)

Table 20. Global Therapeutic Monoclonal Antibodies Drug Sale Price by Company (2021-2026) & (US\$/Ton)

Table 21. Key Manufacturers Therapeutic Monoclonal Antibodies Drug Producing Area Distribution and Sales Area

Table 22. Players Therapeutic Monoclonal Antibodies Drug Products Offered

Table 23. Therapeutic Monoclonal Antibodies Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 24. New Products and Potential Entrants

Table 25. Market M&A Activity & Strategy

Table 26. Global Therapeutic Monoclonal Antibodies Drug Sales by Geographic Region (2021-2026) & (Tons)

Table 27. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share Geographic Region (2021-2026)

Table 28. Global Therapeutic Monoclonal Antibodies Drug Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 29. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Geographic Region (2021-2026)

Table 30. Global Therapeutic Monoclonal Antibodies Drug Sales by Country/Region (2021-2026) & (Tons)

Table 31. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Country/Region (2021-2026)

Table 32. Global Therapeutic Monoclonal Antibodies Drug Revenue by Country/Region (2021-2026) & (\$ millions)

Table 33. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Country/Region (2021-2026)

Table 34. Americas Therapeutic Monoclonal Antibodies Drug Sales by Country (2021-2026) & (Tons)

Table 35. Americas Therapeutic Monoclonal Antibodies Drug Sales Market Share by Country (2021-2026)

Table 36. Americas Therapeutic Monoclonal Antibodies Drug Revenue by Country (2021-2026) & (\$ millions)

Table 37. Americas Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026) & (Tons)

Table 38. Americas Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026) & (Tons)

Table 39. APAC Therapeutic Monoclonal Antibodies Drug Sales by Region (2021-2026) & (Tons)

Table 40. APAC Therapeutic Monoclonal Antibodies Drug Sales Market Share by Region (2021-2026)

Table 41. APAC Therapeutic Monoclonal Antibodies Drug Revenue by Region (2021-2026) & (\$ millions)

Table 42. APAC Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026) & (Tons)

Table 43. APAC Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026) & (Tons)

Table 44. Europe Therapeutic Monoclonal Antibodies Drug Sales by Country (2021-2026) & (Tons)

Table 45. Europe Therapeutic Monoclonal Antibodies Drug Revenue by Country (2021-2026) & (\$ millions)

Table 46. Europe Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026) & (Tons)

Table 47. Europe Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026) & (Tons)

Table 48. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales by Country (2021-2026) & (Tons)

Table 49. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Country (2021-2026)

Table 50. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales by Type (2021-2026) & (Tons)

Table 51. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales by Application (2021-2026) & (Tons)

Table 52. Key Market Drivers & Growth Opportunities of Therapeutic Monoclonal Antibodies Drug

Table 53. Key Market Challenges & Risks of Therapeutic Monoclonal Antibodies Drug

Table 54. Key Industry Trends of Therapeutic Monoclonal Antibodies Drug

Table 55. Therapeutic Monoclonal Antibodies Drug Raw Material

Table 56. Key Suppliers of Raw Materials

Table 57. Therapeutic Monoclonal Antibodies Drug Distributors List

Table 58. Therapeutic Monoclonal Antibodies Drug Customer List

Table 59. Global Therapeutic Monoclonal Antibodies Drug Sales Forecast by Region (2027-2032) & (Tons)

Table 60. Global Therapeutic Monoclonal Antibodies Drug Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 61. Americas Therapeutic Monoclonal Antibodies Drug Sales Forecast by Country (2027-2032) & (Tons)

Table 62. Americas Therapeutic Monoclonal Antibodies Drug Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 63. APAC Therapeutic Monoclonal Antibodies Drug Sales Forecast by Region

(2027-2032) & (Tons)

Table 64. APAC Therapeutic Monoclonal Antibodies Drug Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 65. Europe Therapeutic Monoclonal Antibodies Drug Sales Forecast by Country (2027-2032) & (Tons)

Table 66. Europe Therapeutic Monoclonal Antibodies Drug Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 67. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales Forecast by Country (2027-2032) & (Tons)

Table 68. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 69. Global Therapeutic Monoclonal Antibodies Drug Sales Forecast by Type (2027-2032) & (Tons)

Table 70. Global Therapeutic Monoclonal Antibodies Drug Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 71. Global Therapeutic Monoclonal Antibodies Drug Sales Forecast by Application (2027-2032) & (Tons)

Table 72. Global Therapeutic Monoclonal Antibodies Drug Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 73. AbbVie Basic Information, Therapeutic Monoclonal Antibodies Drug Manufacturing Base, Sales Area and Its Competitors

Table 74. AbbVie Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

Table 75. AbbVie Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 76. AbbVie Main Business

Table 77. AbbVie Latest Developments

Table 78. Johnson & Johnson Basic Information, Therapeutic Monoclonal Antibodies Drug Manufacturing Base, Sales Area and Its Competitors

Table 79. Johnson & Johnson Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

Table 80. Johnson & Johnson Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 81. Johnson & Johnson Main Business

Table 82. Johnson & Johnson Latest Developments

Table 83. Novartis Basic Information, Therapeutic Monoclonal Antibodies Drug Manufacturing Base, Sales Area and Its Competitors

Table 84. Novartis Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

Table 85. Novartis Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 86. Novartis Main Business

Table 87. Novartis Latest Developments

Table 88. Gilead Sciences Basic Information, Therapeutic Monoclonal Antibodies Drug Manufacturing Base, Sales Area and Its Competitors

Table 89. Gilead Sciences Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

Table 90. Gilead Sciences Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 91. Gilead Sciences Main Business

Table 92. Gilead Sciences Latest Developments

Table 93. Roche Basic Information, Therapeutic Monoclonal Antibodies Drug Manufacturing Base, Sales Area and Its Competitors

Table 94. Roche Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

Table 95. Roche Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 96. Roche Main Business

Table 97. Roche Latest Developments

Table 98. Bristol-Myers Squibb Basic Information, Therapeutic Monoclonal Antibodies Drug Manufacturing Base, Sales Area and Its Competitors

Table 99. Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

Table 100. Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 101. Bristol-Myers Squibb Main Business

Table 102. Bristol-Myers Squibb Latest Developments

Table 103. Amgen Basic Information, Therapeutic Monoclonal Antibodies Drug Manufacturing Base, Sales Area and Its Competitors

Table 104. Amgen Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

Table 105. Amgen Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 106. Amgen Main Business

Table 107. Amgen Latest Developments

Table 108. AstraZeneca Basic Information, Therapeutic Monoclonal Antibodies Drug Manufacturing Base, Sales Area and Its Competitors

Table 109. AstraZeneca Therapeutic Monoclonal Antibodies Drug Product Portfolios

and Specifications

Table 110. AstraZeneca Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 111. AstraZeneca Main Business

Table 112. AstraZeneca Latest Developments

Table 113. Merck & Co Basic Information, Therapeutic Monoclonal Antibodies Drug Manufacturing Base, Sales Area and Its Competitors

Table 114. Merck & Co Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

Table 115. Merck & Co Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 116. Merck & Co Main Business

Table 117. Merck & Co Latest Developments

Table 118. Takeda Basic Information, Therapeutic Monoclonal Antibodies Drug Manufacturing Base, Sales Area and Its Competitors

Table 119. Takeda Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

Table 120. Takeda Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 121. Takeda Main Business

Table 122. Takeda Latest Developments

Table 123. Merck KGaA Basic Information, Therapeutic Monoclonal Antibodies Drug Manufacturing Base, Sales Area and Its Competitors

Table 124. Merck KGaA Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

Table 125. Merck KGaA Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 126. Merck KGaA Main Business

Table 127. Merck KGaA Latest Developments

Table 128. Seagen Basic Information, Therapeutic Monoclonal Antibodies Drug Manufacturing Base, Sales Area and Its Competitors

Table 129. Seagen Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

Table 130. Seagen Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 131. Seagen Main Business

Table 132. Seagen Latest Developments

Table 133. Eli Lilly Basic Information, Therapeutic Monoclonal Antibodies Drug Manufacturing Base, Sales Area and Its Competitors

Table 134. Eli Lilly Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

Table 135. Eli Lilly Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 136. Eli Lilly Main Business

Table 137. Eli Lilly Latest Developments

Table 138. Ono Pharmaceutical Basic Information, Therapeutic Monoclonal Antibodies Drug Manufacturing Base, Sales Area and Its Competitors

Table 139. Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

Table 140. Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 141. Ono Pharmaceutical Main Business

Table 142. Ono Pharmaceutical Latest Developments

Table 143. Pfizer Basic Information, Therapeutic Monoclonal Antibodies Drug Manufacturing Base, Sales Area and Its Competitors

Table 144. Pfizer Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

Table 145. Pfizer Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 146. Pfizer Main Business

Table 147. Pfizer Latest Developments

Table 148. Regeneron Basic Information, Therapeutic Monoclonal Antibodies Drug Manufacturing Base, Sales Area and Its Competitors

Table 149. Regeneron Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

Table 150. Regeneron Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 151. Regeneron Main Business

Table 152. Regeneron Latest Developments

Table 153. Innovent Basic Information, Therapeutic Monoclonal Antibodies Drug Manufacturing Base, Sales Area and Its Competitors

Table 154. Innovent Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

Table 155. Innovent Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 156. Innovent Main Business

Table 157. Innovent Latest Developments

Table 158. Hengrui Medicine Basic Information, Therapeutic Monoclonal Antibodies

Drug Manufacturing Base, Sales Area and Its Competitors

Table 159. Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Product Portfolios and Specifications

Table 160. Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 161. Hengrui Medicine Main Business

Table 162. Hengrui Medicine Latest Developments

## List Of Figures

### LIST OF FIGURES

Figure 1. Picture of Therapeutic Monoclonal Antibodies Drug

Figure 2. Therapeutic Monoclonal Antibodies Drug Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Therapeutic Monoclonal Antibodies Drug Sales Growth Rate 2021-2032 (Tons)

Figure 7. Global Therapeutic Monoclonal Antibodies Drug Revenue Growth Rate 2021-2032 (\$ millions)

Figure 8. Therapeutic Monoclonal Antibodies Drug Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 9. Therapeutic Monoclonal Antibodies Drug Sales Market Share by Country/Region (2025)

Figure 10. Therapeutic Monoclonal Antibodies Drug Sales Market Share by Country/Region (2021, 2025 & 2032)

Figure 11. Product Picture of Mouse-derived Antibodies

Figure 12. Product Picture of Chimeric Antibodies

Figure 13. Product Picture of Humanized Antibodies

Figure 14. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Type in 2026

Figure 15. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Type (2021-2026)

Figure 16. Therapeutic Monoclonal Antibodies Drug Consumed in Immune Diseases

Figure 17. Global Therapeutic Monoclonal Antibodies Drug Market: Immune Diseases (2021-2026) & (Tons)

Figure 18. Therapeutic Monoclonal Antibodies Drug Consumed in Cancer

Figure 19. Global Therapeutic Monoclonal Antibodies Drug Market: Cancer (2021-2026) & (Tons)

Figure 20. Therapeutic Monoclonal Antibodies Drug Consumed in Other

Figure 21. Global Therapeutic Monoclonal Antibodies Drug Market: Other (2021-2026) & (Tons)

Figure 22. Global Therapeutic Monoclonal Antibodies Drug Sale Market Share by Application (2025)

Figure 23. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Application in 2026

Figure 24. Therapeutic Monoclonal Antibodies Drug Sales by Company in 2026 (Tons)

Figure 25. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Company in 2026

Figure 26. Therapeutic Monoclonal Antibodies Drug Revenue by Company in 2026 (\$ millions)

Figure 27. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Company in 2026

Figure 28. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Geographic Region (2021-2026)

Figure 29. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Geographic Region in 2026

Figure 30. Americas Therapeutic Monoclonal Antibodies Drug Sales 2021-2026 (Tons)

Figure 31. Americas Therapeutic Monoclonal Antibodies Drug Revenue 2021-2026 (\$ millions)

Figure 32. APAC Therapeutic Monoclonal Antibodies Drug Sales 2021-2026 (Tons)

Figure 33. APAC Therapeutic Monoclonal Antibodies Drug Revenue 2021-2026 (\$ millions)

Figure 34. Europe Therapeutic Monoclonal Antibodies Drug Sales 2021-2026 (Tons)

Figure 35. Europe Therapeutic Monoclonal Antibodies Drug Revenue 2021-2026 (\$ millions)

Figure 36. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales 2021-2026 (Tons)

Figure 37. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Revenue 2021-2026 (\$ millions)

Figure 38. Americas Therapeutic Monoclonal Antibodies Drug Sales Market Share by Country in 2026

Figure 39. Americas Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Country (2021-2026)

Figure 40. Americas Therapeutic Monoclonal Antibodies Drug Sales Market Share by Type (2021-2026)

Figure 41. Americas Therapeutic Monoclonal Antibodies Drug Sales Market Share by Application (2021-2026)

Figure 42. United States Therapeutic Monoclonal Antibodies Drug Revenue Growth 2021-2026 (\$ millions)

Figure 43. Canada Therapeutic Monoclonal Antibodies Drug Revenue Growth 2021-2026 (\$ millions)

Figure 44. Mexico Therapeutic Monoclonal Antibodies Drug Revenue Growth 2021-2026 (\$ millions)

Figure 45. Brazil Therapeutic Monoclonal Antibodies Drug Revenue Growth 2021-2026

(\$ millions)

Figure 46. APAC Therapeutic Monoclonal Antibodies Drug Sales Market Share by Region in 2026

Figure 47. APAC Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Region (2021-2026)

Figure 48. APAC Therapeutic Monoclonal Antibodies Drug Sales Market Share by Type (2021-2026)

Figure 49. APAC Therapeutic Monoclonal Antibodies Drug Sales Market Share by Application (2021-2026)

Figure 50. China Therapeutic Monoclonal Antibodies Drug Revenue Growth 2021-2026 (\$ millions)

Figure 51. Japan Therapeutic Monoclonal Antibodies Drug Revenue Growth 2021-2026 (\$ millions)

Figure 52. South Korea Therapeutic Monoclonal Antibodies Drug Revenue Growth 2021-2026 (\$ millions)

Figure 53. Southeast Asia Therapeutic Monoclonal Antibodies Drug Revenue Growth 2021-2026 (\$ millions)

Figure 54. India Therapeutic Monoclonal Antibodies Drug Revenue Growth 2021-2026 (\$ millions)

Figure 55. Australia Therapeutic Monoclonal Antibodies Drug Revenue Growth 2021-2026 (\$ millions)

Figure 56. China Taiwan Therapeutic Monoclonal Antibodies Drug Revenue Growth 2021-2026 (\$ millions)

Figure 57. Europe Therapeutic Monoclonal Antibodies Drug Sales Market Share by Country in 2026

Figure 58. Europe Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Country (2021-2026)

Figure 59. Europe Therapeutic Monoclonal Antibodies Drug Sales Market Share by Type (2021-2026)

Figure 60. Europe Therapeutic Monoclonal Antibodies Drug Sales Market Share by Application (2021-2026)

Figure 61. Germany Therapeutic Monoclonal Antibodies Drug Revenue Growth 2021-2026 (\$ millions)

Figure 62. France Therapeutic Monoclonal Antibodies Drug Revenue Growth 2021-2026 (\$ millions)

Figure 63. UK Therapeutic Monoclonal Antibodies Drug Revenue Growth 2021-2026 (\$ millions)

Figure 64. Italy Therapeutic Monoclonal Antibodies Drug Revenue Growth 2021-2026 (\$ millions)

- Figure 65. Russia Therapeutic Monoclonal Antibodies Drug Revenue Growth 2021-2026 (\$ millions)
- Figure 66. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales Market Share by Country (2021-2026)
- Figure 67. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales Market Share by Type (2021-2026)
- Figure 68. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales Market Share by Application (2021-2026)
- Figure 69. Egypt Therapeutic Monoclonal Antibodies Drug Revenue Growth 2021-2026 (\$ millions)
- Figure 70. South Africa Therapeutic Monoclonal Antibodies Drug Revenue Growth 2021-2026 (\$ millions)
- Figure 71. Israel Therapeutic Monoclonal Antibodies Drug Revenue Growth 2021-2026 (\$ millions)
- Figure 72. Turkey Therapeutic Monoclonal Antibodies Drug Revenue Growth 2021-2026 (\$ millions)
- Figure 73. GCC Countries Therapeutic Monoclonal Antibodies Drug Revenue Growth 2021-2026 (\$ millions)
- Figure 74. Manufacturing Cost Structure Analysis of Therapeutic Monoclonal Antibodies Drug in 2026
- Figure 75. Manufacturing Process Analysis of Therapeutic Monoclonal Antibodies Drug
- Figure 76. Industry Chain Structure of Therapeutic Monoclonal Antibodies Drug
- Figure 77. Channels of Distribution
- Figure 78. Global Therapeutic Monoclonal Antibodies Drug Sales Market Forecast by Region (2027-2032)
- Figure 79. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share Forecast by Region (2027-2032)
- Figure 80. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share Forecast by Type (2027-2032)
- Figure 81. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share Forecast by Type (2027-2032)
- Figure 82. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share Forecast by Application (2027-2032)
- Figure 83. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share Forecast by Application (2027-2032)

## I would like to order

Product name: Global Therapeutic Monoclonal Antibodies Drug Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/GFF0370EDA4DEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GFF0370EDA4DEN.html>